SynthesisNutrients2023
Selected Flavonols in Breast and Gynecological Cancer: A Systematic Review.
Synthesis in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Impact of Nutritional Supplements and Antioxidants in the Treatment of Breast Cancer: A Systematic Review.Nutrients · 2026Pooled it
- Targeted Folate-Chitosan Nanoformulations of Quercetin andPharmaceuticals (Basel, Switzerland) · 2026Article
- Potential Role of Polyphenols in Platelet Aggregation and Blood Coagulation.Journal of cardiovascular development and disease · 2026Review
- Data mining and experimental validation identify a core herb combination as a therapeutic agent for malignant lymphoma.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Quercetin-loaded silicon dioxide-graphene nanoparticles promotes M2 macrophage reprogramming in mycoplasma-induced pneumonia.Journal of inflammation (London, England) · 2026Article
- Progress in the antitumor molecular mechanisms of Isorhamnetin.Discover oncology · 2025Review
- Antimicrobial, Antioxidant, Antitumor, and Anti-Inflammatory Properties ofAntioxidants (Basel, Switzerland) · 2025Article
- Pre- and post-diagnosis dietary total antioxidant capacity and overall survival in patients with ovarian cancer: a prospective cohort study.Nutrition journal · 2025Article
- Design, synthesis, molecular docking and molecular dynamics studies of some 3-methoxy flavone derivatives as an anti-breast cancer agent.Discover oncology · 2025Article
- Galangin promotes apoptosis by upregulating the pro-apoptotic gene BAX in triple-negative breast cancer.Journal of the Egyptian National Cancer Institute · 2024Article
- Flavonoids: Antioxidant Powerhouses and Their Role in Nanomedicine.Antioxidants (Basel, Switzerland) · 2024Review
- Therapeutic Implications of Dietary Polyphenols-Loaded Nanoemulsions in Cancer Therapy.ACS applied bio materials · 2024Review
- Effect of Niosomal Encapsulation of Quercetin and Silymarin and their Combination on Dimethylnitrosoamine-induced and Phenobarbital promoted Hepatocellular Carcinoma in Rat Model.Current drug discovery technologies · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The consumption of foods that are rich in phenolic compounds has chemopreventive effects on many cancers, including breast cancer, ovarian cancer, and endometrial cancer. A wide spectrum of their health-promoting properties such as antioxidant, anti-inflammatory, and anticancer activities, has been demonstrated. This paper analyzes the mechanisms of the anticancer action of selected common flavonols, including kemferol, myricetin, quercetin, fisetin, galangin, isorhamnetin, and morin, in preclinical studies, with particular emphasis on in vitro studies in gynecological cancers and breast cancer. In the future, these compounds may find applications in the prevention and treatment of gynecological cancers and breast cancer, but this requires further, more advanced research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.